Literature DB >> 8883968

Quantification of uPA receptor expression in human breast cancer cell lines by cRT-PCR.

G Sliutz1, H Eder, H Koelbl, C Tempfer, L Auerbach, C Schneeberger, C Kainz, R Zeillinger.   

Abstract

The conversion of plasminogen to active plasmin is thought to be a crucial step in the process of extracellular matrix degradation associated with metastatic spread. Activation of plasminogen is initiated by urokinase plasminogen activator (uPA). The binding of uPA to the uPA cell surface receptor (uPA-R) accelerates plasmin generation from plasminogen and localizes uPA activity to the cell surface. We investigated the mRNA-expression of uPA-R in 19 different human breast cancer cell lines. In a competitive reverse transcription polymerase chain reaction (cRT-PCR) we simultaneously co-amplified two different RNA templates bearing the same primer recognition sequences, the cell line RNA and a known amount of an in vitro synthesized uPA-R-RNA internal standard. We analyzed the two PCR products differing 50 bp in size by agarose gel electrophoresis and calculated the initial uPA-R-RNA template concentration from the relative intensities of the bands quantified by video densitometry. We grouped the investigated cell lines according to their in vitro invasiveness according to literature. Cell lines with a high potential of invasiveness showed a higher expression of uPA-R compared to those with a low potential of invasiveness (Student's t-test, p 0.04). In addition to that we compared the uPA-R mRNA levels with uPA-R, uPA, and PAI-1 protein levels in culture supernatants and cell lysates. The obtained results in breast cancer cell lines with different invasiveness and in benign epithelial cell lines revealed the complex cooperation of the urokinase type proteolytic pathway. uPA, uPA-R, and PAI-1 are to be considered as a diagnostic tool rather than assaying a particular molecule alone. Our findings support the hypothesis that the urokinase proteolytic pathway plays a central role in the acquisition of an invasive phenotype and favors its potential use as a prognostic marker in patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8883968     DOI: 10.1007/bf01806814

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  15 in total

1.  Competitive PCR.

Authors:  P D Siebert; J W Larrick
Journal:  Nature       Date:  1992-10-08       Impact factor: 49.962

2.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

3.  Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.

Authors:  F D Kury; C Schneeberger; G Sliutz; E Kubista; H Salzer; M Medl; S Leodolter; H Swoboda; R Zeillinger; J Spona
Journal:  Oncogene       Date:  1990-09       Impact factor: 9.867

4.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants.

Authors:  N Behrendt; E Rønne; M Ploug; T Petri; D Løber; L S Nielsen; W D Schleuning; F Blasi; E Appella; K Danø
Journal:  J Biol Chem       Date:  1990-04-15       Impact factor: 5.157

5.  Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays.

Authors:  S N Bae; G Arand; H Azzam; P Pavasant; J Torri; T L Frandsen; E W Thompson
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.

Authors:  H Pedersen; N Brünner; D Francis; K Osterlind; E Rønne; H H Hansen; K Danø; J Grøndahl-Hansen
Journal:  Cancer Res       Date:  1994-09-01       Impact factor: 12.701

7.  Plasminogen activation initiated by single-chain urokinase-type plasminogen activator. Potentiation by U937 monocytes.

Authors:  V Ellis; M F Scully; V V Kakkar
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

8.  Quantitation of mRNA by the polymerase chain reaction.

Authors:  A M Wang; M V Doyle; D F Mark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

Authors:  A L Roldan; M V Cubellis; M T Masucci; N Behrendt; L R Lund; K Danø; E Appella; F Blasi
Journal:  EMBO J       Date:  1990-02       Impact factor: 11.598

10.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes.

Authors:  A Estreicher; J Mühlhauser; J L Carpentier; L Orci; J D Vassalli
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  5 in total

1.  The human chemokine receptor CCRL2 suppresses chemotaxis and invasion by blocking CCL2-induced phosphorylation of p38 MAPK in human breast cancer cells.

Authors:  Lei-Ping Wang; Jun Cao; Jian Zhang; Bi-Yun Wang; Xi-Chun Hu; Zhi-Min Shao; Zhong-Hua Wang; Zhou-Luo Ou
Journal:  Med Oncol       Date:  2015-10-20       Impact factor: 3.064

2.  In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.

Authors:  Yuqi Jing; Marcela Toro Bejarano; Julia Zaias; Jaime R Merchan
Journal:  Breast Cancer Res Treat       Date:  2014-12-18       Impact factor: 4.872

3.  Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Authors:  Yuqi Jing; Valery Chavez; Yuguang Ban; Nicolas Acquavella; Doraya El-Ashry; Alexey Pronin; Xi Chen; Jaime R Merchan
Journal:  Mol Cancer Res       Date:  2017-07-05       Impact factor: 5.852

4.  Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance.

Authors:  Aaron M LeBeau; Natalia Sevillano; Mandy L King; Sai Duriseti; Stephanie T Murphy; Charles S Craik; Laura L Murphy; Henry F VanBrocklin
Journal:  Theranostics       Date:  2014-01-18       Impact factor: 11.556

5.  Low expression of TFPI-2 associated with poor survival outcome in patients with breast cancer.

Authors:  Cheng Xu; Huijun Wang; Hongyu He; Fengyun Zheng; Yating Chen; Jin Zhang; Xiaoyan Lin; Duan Ma; Hongwei Zhang
Journal:  BMC Cancer       Date:  2013-03-15       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.